Abstract

T cells play a critical role in controlling viral infection; however, the mechanisms regulating their responses remain incompletely understood. Here, we investigated the role of topoisomerase IIA (Top2α, an enzyme that is essential in resolving entangled DNA strands during replication) in telomeric DNA damage and T cell dysfunction during viral infection. We demonstrated that T cells derived from patients with chronic viral (HBV, HCV, and HIV) infection had lower Top2α protein levels and enzymatic activity, along with an accumulation of the Top2α cleavage complex (Top2cc) in genomic DNA. In addition, T cells from virally infected subjects with lower Top2α levels were vulnerable to Top2α inhibitor-induced cell apoptosis, indicating an important role for Top2α in preventing DNA topological disruption and cell death. Using Top2α inhibitor (ICRF193 or Etoposide)-treated primary T cells as a model, we demonstrated that disrupting the DNA topology promoted DNA damage and T cell apoptosis via Top2cc accumulation that is associated with protein-DNA breaks (PDB) at genomic DNA. Disruption of the DNA topology was likely due to diminished expression of tyrosyl-DNA phosphodiesterase 2 (TDP2), which was inhibited in T cells in vitro by Top2α inhibitor and in vivo by chronic viral infection. These results suggest that immune-evasive viruses (HBV, HCV, and HIV) can disrupt T cell DNA topology as a mechanism of dysregulating host immunity and establishing chronic infection. Thus, restoring the DNA topologic machinery may serve as a novel strategy to protect T cells from unwanted DNA damage and to maintain immune competence.

Details

Title
Inhibition of topoisomerase IIA (Top2α) induces telomeric DNA damage and T cell dysfunction during chronic viral infection
Author
Dang Xindi 1 ; Ogbu, Stella C 1 ; Zhao, Juan 1 ; Nguyen Lam Ngoc Thao 1 ; Cao Dechao 1 ; Nguyen Lam Nhat 1 ; Khanal Sushant 1 ; Schank Madison 1 ; Thakuri Bal Krishna Chand 1 ; Wu, Xiao Y 1 ; Morrison, Zheng D 1 ; Zhang, Jinyu 1 ; Li Zhengke 1 ; El Gazzar Mohamed 2 ; Shunbin, Ning 1 ; Wang, Ling 1 ; Wang, Zhengqiang 3 ; Moorman, Jonathan P 4 ; Yao, Zhi Q 4 

 East Tennessee State University, Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673); Quillen College of Medicine, ETSU, Division of Infectious, Inflammatory and Immunologic Diseases, Department of Internal Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673) 
 East Tennessee State University, Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673) 
 University of Minnesota, Center for Drug Design, College of Pharmacy, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657) 
 East Tennessee State University, Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673); Quillen College of Medicine, ETSU, Division of Infectious, Inflammatory and Immunologic Diseases, Department of Internal Medicine, Johnson City, USA (GRID:grid.255381.8) (ISNI:0000 0001 2180 1673); Hepatitis (HCV/HBV/HIV) Program, James H. Quillen VA Medical Center, Department of Veterans Affairs, Johnson City, USA (GRID:grid.417066.2) (ISNI:0000 0004 0420 481X) 
Publication year
2020
Publication date
Mar 2020
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2379539707
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.